The expression of SOX2 correlates with poor prognosis for stage I lung adenocarcinoma, squamous cell carcinoma, gastric carcinoma, small cell lung cancer, and ovarian carcinoma [35,36]. Here, SOX2 is linked to ovarian carcinoma.